|
PROGRAM OVERVIEW
In one of history's most difficult financial environments, early-stage companies seeking funding must look at diverse ways of obtaining it. Jeff Stein, President & Chief Executive Officer of TRIUS Therapeutics, will provide a special case study that examines the series of financing mechanisms used to build Trius from its inception 2007 to the public company that it is today. In what promises to be an informative and compelling talk, Stein will examine Trius' five stages of growth—SBIR funding supplemented by working capital from angel investors, subsequent rounds of venture financing co-invested by angels, large federal grant funding from the DoD (DTRA and NIAID) and a public/private partnership with Scripps Institution of Oceanography, an initial public offering and most recently, a big pharma partnership.
Nikolay Savchuk, Managing Director at Torrey Pines Investment (TPI), a San Diego based venture company, will highlight the innovative aspects of TPI investment model. During his talk, Savchuk will discuss several case studies from company's investment portfolio, such as an innovative deal structure with orphan drug discovery company Afraxis which allowed the San Diego start-up to advance its primary program and expand with adding an extra platform while operating in a super-efficient, semi-virtual model. Far from home TPI advised on creating of an innovative oncoimmunology company NewVac, with support of a large Skolkovo foundation grant (backed by the government) and further advanced on licensing of personalized oncovaccines to sell on the emerging markets. TPI also processed deal with Hoffman La Roche which enabled creation of a pioneering tech transfer business model and specialty pharma in HIV products. Savchuk's talk could be instructive in promoting international cooperation, access to capital and emerging markets for SoCal companies and research groups.
WHO SHOULD ATTEND
This Financial Forum is designed for entrepreneurs, start-up companies, and independent researchers developing innovative technologies; investors interested in pursuing alternative financing for portfolio companies; university researchers and technology transfer professionals; CEOs and CFOs of existing companies; and service providers engaged in the emerging technology/life sciences community.
AGENDA
2:30pm Registration/Networking
3:00pm Welcome Remarks
- Louis Coffman, Vice President, Sanford Consortium for Regenerative Medicine
- Julia Brown, UC San Diego Board of Trustees
3:10pm Innovative Financing Models for Early-Stage Companies
- TRIUS Therapeutics Case Study
Jeff Stein, President & CEO, TRIUS Therapeutics
- Torrey Pines Investment Case Study & Other Success Stories
Nikolay Savchuk, Managing Director, Torrey Pines Investment
4:00pm Moderated Q&A Discussion
4:30pm Networking Reception
5:30pm Program Concludes
ABOUT THE SPEAKERS
Jeff Stein
President & Chief Executive Officer, Trius Therapeutics
Jeff Stein has served as President and Chief Executive Officer of Trius Therapeutics since February 2007, and on its board of directors since 2005. From 2005 through 2007, Dr. Stein was a Kauffman Fellow with the venture capital firm Sofinnova Ventures. He has also served as a Venture Partner with Sofinnova Ventures from 2007 until 2010 and as Director of Venture Development for the UC San Diego from 2005 to 2006. From 1999 to 2005, Dr. Stein served as Executive Vice President, Chief Scientific Officer and a member of the board of directors of Quorex Pharmaceuticals, an anti-infectives company he founded in 1999, which was acquired by Pfizer in 2005. From 1995 to 1999, Dr. Stein was a scientist with Diversa Corporation where he most recently served as Principal Scientist and head of the anti-infectives discovery team. From 1993 to 1995, Dr. Stein served as Principal Scientist with the Agouron Institute, a private research institution, where he conducted research in bacterial genetics. From 1991 to 1993, he was an Alexander Hollaendar Distinguished Postdoctoral Fellow with the California Institute of Technology. Dr. Stein holds a Ph.D. in biochemistry and microbiology from UC San Diego.
Nikolay Savchuk
Managing Director, Torrey Pines Investment
Nikolay Savchuk is Managing Director at Torrey Pines Investment (TPI); Chairman of Viriom Ltd., NewVac Ltd., TeaRx Ltd. and Chemical Diversity Research Institute in Moscow, Russia; and serves on the board of ChemRar Hi Tech Center in Moscow, Russia. He has been leading the TPI investment team since 2002. Savchuk is a founder of the Inel Group of IT and media companies in Singapore and Russia, and was an industry representative to the Russian government's Pharma 2020 initiative. Nikolay is an advisor and expert of the Agency Of Strategic Initiatives of the Russian government. He holds a Ph.D. in Mathematics from the Moscow Institute of Physics and Technology.
QUESTIONS?
Please contact Taylor Peterson at (858) 964-1341
or tpeterson@connect.org
|
|
